OPEN ACCESS Freely available online

ISSN: 2153-2435
Pharmaceutica Analytica Acta

Opinion article

An Overview of Process Validation in Pharmaceutical Analysis

Kathleen M. Kantak*

Department of Psychological and Sciences, University of Boston, Boston, United States of America

DESCRIPTION

Process validation is defined by the FDA as the gathering and evaluation of data, from the process design stage through commercial production that establishes scientific evidence that a process is capable of consistently delivering high-quality product. The initial validation initiatives concentrated on the procedures involved in producing these goods, but they quickly expanded to include environmental control, media fill, equipment sanitization, and purified water production.

Process validation this sort of validation shows documented proof that the process will consistently generate a product that respects all of the established quality attributes and criteria. Process validation also ensures that the process is repeatable and reduces the risk of manufacturing issues, resulting in an increase in production of predetermined quality. It can be classified into four types based on the stage of production under Prospective validation, Concurrent validation, Retro specific validation, and revalidation. The establishment of written evidence that a certain process (such as the fabrication of pharmaceutical dosage forms) will consistently produce a product satisfying its set parameters and quality features is known as process validation.

According to the FDA, product quality assurance is derived from careful and systematic attention to a number of important factors, including the selection of quality components and materials, adequate product and process design, and process (statistical) control through in-process and end-product testing. Thus, a high degree of confidence may be built that all individual manufactured units in a particular batch or succession of batches that satisfy criteria will be acceptable through thorough design (qualification) and validation of both the process and its will be acceptable. Cleaning validation: Cleaning validation is a documented set-up that ensures that a certain system/equipment or section of equipment is cleaned to a predetermined quality and within accepted limits on a regular basis. Various contaminants, including as lubricants, airborne pollutants, prepared product residues, and bacteria, can contaminate pharmaceutical goods. As a result, a proper cleaning method is critical in preventing contamination and cross contamination.

Validation Elements, Validation requires qualification first. The following are included in the qualification Design Qualification (DQ) The compliance of the design with Good Manufacture Practice should be demonstrated in this qualification. The design principles should be such that they achieve the GMP objectives for equipment. The mechanical drawings and design features provided by the equipment's maker should be scrutinised. Qualification for Installation (IQ) on new or updated facilities, systems, and equipment, installation qualification should be performed. The installation qualification should comprise the following essential components. The operating working instructions and maintenance needs of the provider, as well as their calibration requirements, are collected. Verification of construction materials Spare parts and maintenance sources.

Operational Qualification (OQ), which should come after IQ, should comprise the tests based on a thorough understanding of the processes, systems, and equipment. Establishing lower and upper operational limits these are sometimes referred to as 'worst case' scenarios. Qualification for Performance (PQ) following the completion of IQ and OQ, PQ is the next qualification to be completed. Tests with manufacturing materials, substitutions, or simulated products should be included in the PQ. These can be created using process and facility expertise, as well as systems and equipment knowledge. Conditions having upper and lower limitations will be included in the tests.

Correspondence to: Kathleen M. Kantak. Department of Psychological and Sciences, University of Boston, Boston, United States of America, E-mail: kantak.kathleem@gmail.com

Received: 02-May-2022, Manuscript no: PAA-22-17097, **Editorial assigned**: 06-May-2022, PreQC no: PAA-22-17097 (PQ), **Reviewed**: 23-May-2022, QC no: PAA-22-17097, **Revised**: 31-May-2022, Manuscript no: PAA-22-17097 (R), **Published:** 07-Jun-2022, DOI: 10.35248/2153-2435.22.13.672

Citation: Kantak MK(2022) An Overview of Process Validation in Pharmaceutical Analysis. Pharm Anal Acta. 13:672